Prevalence and Characteristics of Rheumatoid-Associated Autoantibodies in Patients with COVID-19
Chen Xu,1,* Junli Fan,1,* Yi Luo,1,* Ziwu Zhao,1,* Peng Tang,1,* Gui Yang,1 Yunbao Pan,1 Shuang Guo,1 Yingjuan Liu,1 Yong Xiong,2 Wen Xie,1 Xinghua Long1 1Department of Laboratory Medicine, Zhongnan Hospital of Wuhan University, Wuhan, People’s Republic of Chi...
Guardado en:
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/a4131d2bb6134cd19d5bee448f18067c |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:a4131d2bb6134cd19d5bee448f18067c |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:a4131d2bb6134cd19d5bee448f18067c2021-12-02T16:39:49ZPrevalence and Characteristics of Rheumatoid-Associated Autoantibodies in Patients with COVID-191178-7031https://doaj.org/article/a4131d2bb6134cd19d5bee448f18067c2021-07-01T00:00:00Zhttps://www.dovepress.com/prevalence-and-characteristics-of-rheumatoid-associated-autoantibodies-peer-reviewed-fulltext-article-JIRhttps://doaj.org/toc/1178-7031Chen Xu,1,* Junli Fan,1,* Yi Luo,1,* Ziwu Zhao,1,* Peng Tang,1,* Gui Yang,1 Yunbao Pan,1 Shuang Guo,1 Yingjuan Liu,1 Yong Xiong,2 Wen Xie,1 Xinghua Long1 1Department of Laboratory Medicine, Zhongnan Hospital of Wuhan University, Wuhan, People’s Republic of China; 2Department of infectious diseases, Zhongnan Hospital of Wuhan University, Wuhan, People’s Republic of China*These authors contributed equally to this workCorrespondence: Xinghua Long; Wen XieDepartment of Laboratory Medicine, Zhongnan Hospital of Wuhan University, Wuhan, People’s Republic of ChinaEmail zhoulongxinghua@qq.com; whxw007@126.comObjective: Patients with rheumatic immune diseases were more likely to develop severe or critical COVID-19. We aimed to determine whether rheumatoid factor antibodies were present in COVID patients and the level and type of rheumatoid factor antibodies produced in COVID-19 patients were related to the degree of the patient’s condition. The study also aimed to determine the prevalence and characteristics of rheumatoid factor antibodies in patients with COVID-19.Methods: Sera collected from 129 patients with COVID-19 were tested for rheumatoid factor antibodies by ELISA. Five patients were tracked for several months to monitor dynamic changes of these antibodies.Results: Rheumatoid-associated autoantibodies were detected in 20.16% of patients (26/129) following infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In addition, IgM-RF was primarily present in critically ill patients, while IgA-RF was mainly present in mild patients. Five patients were able to track for several months to monitor dynamic changes of these antibodies. Rheumatoid factor antibodies peaks in the later phase of the disease and last for longer time. Anti-Jo-1 antibody was found in one of the five patients.Conclusion: This was the case series report that rheumatoid-associated autoantibodies are present in patients with COVID-19. The clinical significance of these antibodies was not fully understood and needed further characterization. These autoantibodies are related to the severity of the patient’s disease and exist for a long time in the patient’s body, while their impact on the patient’s health is unknown.Keywords: rheumatoid factor, IgA-RF, IgG-RF, IgM-RF, anti-Jo-1, COVID-19, SARS-CoV-2Xu CFan JLuo YZhao ZTang PYang GPan YGuo SLiu YXiong YXie WLong XDove Medical Pressarticlerheumatoid factoriga-rfigg-rfigm-rfanti-jo-1covid-19sars-cov-2PathologyRB1-214Therapeutics. PharmacologyRM1-950ENJournal of Inflammation Research, Vol Volume 14, Pp 3123-3128 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
rheumatoid factor iga-rf igg-rf igm-rf anti-jo-1 covid-19 sars-cov-2 Pathology RB1-214 Therapeutics. Pharmacology RM1-950 |
| spellingShingle |
rheumatoid factor iga-rf igg-rf igm-rf anti-jo-1 covid-19 sars-cov-2 Pathology RB1-214 Therapeutics. Pharmacology RM1-950 Xu C Fan J Luo Y Zhao Z Tang P Yang G Pan Y Guo S Liu Y Xiong Y Xie W Long X Prevalence and Characteristics of Rheumatoid-Associated Autoantibodies in Patients with COVID-19 |
| description |
Chen Xu,1,* Junli Fan,1,* Yi Luo,1,* Ziwu Zhao,1,* Peng Tang,1,* Gui Yang,1 Yunbao Pan,1 Shuang Guo,1 Yingjuan Liu,1 Yong Xiong,2 Wen Xie,1 Xinghua Long1 1Department of Laboratory Medicine, Zhongnan Hospital of Wuhan University, Wuhan, People’s Republic of China; 2Department of infectious diseases, Zhongnan Hospital of Wuhan University, Wuhan, People’s Republic of China*These authors contributed equally to this workCorrespondence: Xinghua Long; Wen XieDepartment of Laboratory Medicine, Zhongnan Hospital of Wuhan University, Wuhan, People’s Republic of ChinaEmail zhoulongxinghua@qq.com; whxw007@126.comObjective: Patients with rheumatic immune diseases were more likely to develop severe or critical COVID-19. We aimed to determine whether rheumatoid factor antibodies were present in COVID patients and the level and type of rheumatoid factor antibodies produced in COVID-19 patients were related to the degree of the patient’s condition. The study also aimed to determine the prevalence and characteristics of rheumatoid factor antibodies in patients with COVID-19.Methods: Sera collected from 129 patients with COVID-19 were tested for rheumatoid factor antibodies by ELISA. Five patients were tracked for several months to monitor dynamic changes of these antibodies.Results: Rheumatoid-associated autoantibodies were detected in 20.16% of patients (26/129) following infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In addition, IgM-RF was primarily present in critically ill patients, while IgA-RF was mainly present in mild patients. Five patients were able to track for several months to monitor dynamic changes of these antibodies. Rheumatoid factor antibodies peaks in the later phase of the disease and last for longer time. Anti-Jo-1 antibody was found in one of the five patients.Conclusion: This was the case series report that rheumatoid-associated autoantibodies are present in patients with COVID-19. The clinical significance of these antibodies was not fully understood and needed further characterization. These autoantibodies are related to the severity of the patient’s disease and exist for a long time in the patient’s body, while their impact on the patient’s health is unknown.Keywords: rheumatoid factor, IgA-RF, IgG-RF, IgM-RF, anti-Jo-1, COVID-19, SARS-CoV-2 |
| format |
article |
| author |
Xu C Fan J Luo Y Zhao Z Tang P Yang G Pan Y Guo S Liu Y Xiong Y Xie W Long X |
| author_facet |
Xu C Fan J Luo Y Zhao Z Tang P Yang G Pan Y Guo S Liu Y Xiong Y Xie W Long X |
| author_sort |
Xu C |
| title |
Prevalence and Characteristics of Rheumatoid-Associated Autoantibodies in Patients with COVID-19 |
| title_short |
Prevalence and Characteristics of Rheumatoid-Associated Autoantibodies in Patients with COVID-19 |
| title_full |
Prevalence and Characteristics of Rheumatoid-Associated Autoantibodies in Patients with COVID-19 |
| title_fullStr |
Prevalence and Characteristics of Rheumatoid-Associated Autoantibodies in Patients with COVID-19 |
| title_full_unstemmed |
Prevalence and Characteristics of Rheumatoid-Associated Autoantibodies in Patients with COVID-19 |
| title_sort |
prevalence and characteristics of rheumatoid-associated autoantibodies in patients with covid-19 |
| publisher |
Dove Medical Press |
| publishDate |
2021 |
| url |
https://doaj.org/article/a4131d2bb6134cd19d5bee448f18067c |
| work_keys_str_mv |
AT xuc prevalenceandcharacteristicsofrheumatoidassociatedautoantibodiesinpatientswithcovid19 AT fanj prevalenceandcharacteristicsofrheumatoidassociatedautoantibodiesinpatientswithcovid19 AT luoy prevalenceandcharacteristicsofrheumatoidassociatedautoantibodiesinpatientswithcovid19 AT zhaoz prevalenceandcharacteristicsofrheumatoidassociatedautoantibodiesinpatientswithcovid19 AT tangp prevalenceandcharacteristicsofrheumatoidassociatedautoantibodiesinpatientswithcovid19 AT yangg prevalenceandcharacteristicsofrheumatoidassociatedautoantibodiesinpatientswithcovid19 AT pany prevalenceandcharacteristicsofrheumatoidassociatedautoantibodiesinpatientswithcovid19 AT guos prevalenceandcharacteristicsofrheumatoidassociatedautoantibodiesinpatientswithcovid19 AT liuy prevalenceandcharacteristicsofrheumatoidassociatedautoantibodiesinpatientswithcovid19 AT xiongy prevalenceandcharacteristicsofrheumatoidassociatedautoantibodiesinpatientswithcovid19 AT xiew prevalenceandcharacteristicsofrheumatoidassociatedautoantibodiesinpatientswithcovid19 AT longx prevalenceandcharacteristicsofrheumatoidassociatedautoantibodiesinpatientswithcovid19 |
| _version_ |
1718383589735792640 |